SINT

SINTX Technologies, Inc. Common Stock (SINT) | Rumor.io

SINTX Technologies

SINT

Attention (50-day avg)0%

Attention rank (50-day avg)#3,227

Bullish sentiment (50-day avg)4%

Price to earnings ratio-0.32

Market capitalization13.3M

Earnings per share-5.48

Dividend yield (TTM)—

Revenue (annual)729K

Net income (annual)-10.4M

Social

What share of all stock conversation is about SINT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 13

Sintx Technologies, Inc. (SINT) has regained compliance with the minimum stockholders' equity requirement of $2.5 million, reporting $4,830,000 in equity.
The company's laser cladding patent, which can be applied and FDA-approved in a matter of months, has been underutilized, with no basic pilot program implemented despite being acquired 1.5 years ago.
Sintx Technologies has potential for significant revenue growth, with an estimated market cap of $1.5-2 billion by year 5, according to a three-way deal between Sintx, Ned Medical, and Varian.

Generated by AI

Sentiment

Of the messages about SINT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	55.89% -25.82
Bearish	—	—	—	44.11% +25.82

Bullish· Oct 21

Sintx Technologies has FDA approval, giving it access to a $4 billion sector with significant potential.
The company's CEO took advantage of a recent price drop, indicating confidence in the stock's future.
Sintx's partnerships and product offerings are expected to play a crucial role across multiple industries, making its Si3N4 material highly valuable.

Bearish· Oct 20

$SINT's price is being suppressed due to manipulation in dark pools, preventing it from reaching its full potential.
The company's frequent dilution of shares can make even positive news less impactful on the stock price.
$SINT's high levels of dilution and capital raising concerns are causing investors to lose confidence in the stock.

Generated by AI

Topics

Of the messages about SINT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	89.87%
Analysts	—	—	—	4.43%
Controversies	—	—	—	2.53%
Earnings	—	—	—	1.27%
Macro	—	—	—	0%
Technical Analysis	—	—	—	1.9%

Announcements· Sep 3

SINTX Technologies published a landmark study demonstrating that its silicon nitride material exhibits broad-spectrum antiviral activity, including a 99.97% reduction in SARS-CoV-2 within 10 minutes.
The study's findings support the use of silicon nitride as a next-generation infection-prevention additive, with potential applications in wound dressings, surgical sutures, masks, hospital bedding, and HEPA filters.
The company's silicon nitride material releases nitrogen-based species that damage viral RNA and proteins without harming surrounding tissue, offering safety advantages over copper, silver, or zinc.

Technical Analysis· Feb 19

The price of $SINT has shown a bullish reversal and is forming a tightening range, with a potential pivot over its local lower high for confirmation.
The stock is testing key levels, including a support level at $4.80 and a resistance level at $5.30, with volume still flowing and large scalps happening.
The 200-day SMA on the daily chart is at $4.87, with some room for daily movement to the left, and the stock is also showing signs of being overbought on the stochastic oscillator.

Generated by AI

Community

Of the messages about SINT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	42.49%
Newcomers	—	—	0%	57.51%

Regulars· Aug 12

Sintx Technologies has been directly selling shares into the market to strengthen liquidity, and has approximately $3.6 million in cash and $5.1 million in ATM capacity.
A deal between Sintx and Varian Medical, which invested in Sintx's partner Ned Medical, has been validated and is on record, despite not being disclosed by Sintx management.
Sintx's technology is considered valuable, with Varian investing in it and Sintx's material being essential for Ned's Combisphere product, and Sintx's patent could have led to FDA clearance with Zimmer in 30 days.

Newcomers· Sep 3

Newcomers are focused on the low float of $SINT, which could lead to significant price movements.
Some newcomers are watching $SINT closely due to its recent price spikes and a machine learning sell prediction.
Others are taking a cautious approach, wondering if the recent sell alert is a smart exit or too early to bail.

Generated by AI

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. Gregg Honigblum, Chief Inve

21d agoYahoo Finance

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1mo agoYahoo Finance

SINTX regains Nasdaq compliance with stockholders’ equity

1mo agoInvesting.com

SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement

SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintai

1mo agoYahoo Finance

H.C. Wainwright reiterates Buy on SINTX Tech stock, $10 target

1mo agoInvesting.com

Also Discussed

Investors talking about SINT also mention

#	Name	Attention
1	FREE - Whole Earth Brands, Inc.	——
2	NLTX - Neoleukin Therapeutics, Inc.	——
3	NovaBay Pharmaceuticals, Inc.NBY	0%0
4	Ascent Solar Technologies, Inc.ASTI	0%0
5	Net Element IncNETE	0%0
6	Greenwave Technology Solutions, Inc.GWAV	0%0
7	XOMA CorporationXOMA	0%0
8	Vislink Technologies Inc.VISL	0%0
9	Viveve Medical Inc.VIVE	0%0
10	Corgi All Commodities 2x Daily ETFXCOM	0%0

SINTX Technologies, Inc. Common Stock

Healthcare
Medical Devices

SINTX Technologies, Inc. Common Stock represents SINTX Technologies, Inc., an advanced ceramics company focused on silicon nitride–based materials and medical technologies. SINTX develops, manufactures, and commercializes biomaterials, components, and related products for biomedical, technical, and antipathogenic applications. Its portfolio includes solid and porous silicon nitride materials, silicon nitride powders and coatings, composite materials, and finished medical device products used in areas such as spinal, foot and ankle, dental, and joint reconstruction. The company also supports contract manufacturing and other advanced ceramics opportunities, using its materials science platform for both medical and high-value industrial applications. Headquartered in Salt Lake City, Utah, SINTX plays a specialized role in the healthcare materials market by supplying high-performance ceramic solutions designed for durability, biocompatibility, and antimicrobial properties.

Website

Location

1885 West 2100 South

Salt Lake City, UT, 84119

United States

Social

What share of all stock conversation is about SINT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 13

Sintx Technologies, Inc. (SINT) has regained compliance with the minimum stockholders' equity requirement of $2.5 million, reporting $4,830,000 in equity.
The company's laser cladding patent, which can be applied and FDA-approved in a matter of months, has been underutilized, with no basic pilot program implemented despite being acquired 1.5 years ago.
Sintx Technologies has potential for significant revenue growth, with an estimated market cap of $1.5-2 billion by year 5, according to a three-way deal between Sintx, Ned Medical, and Varian.

Generated by AI

Sentiment

Of the messages about SINT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	55.89% -25.82
Bearish	—	—	—	44.11% +25.82

Bullish· Oct 21

Sintx Technologies has FDA approval, giving it access to a $4 billion sector with significant potential.
The company's CEO took advantage of a recent price drop, indicating confidence in the stock's future.
Sintx's partnerships and product offerings are expected to play a crucial role across multiple industries, making its Si3N4 material highly valuable.

Bearish· Oct 20

$SINT's price is being suppressed due to manipulation in dark pools, preventing it from reaching its full potential.
The company's frequent dilution of shares can make even positive news less impactful on the stock price.
$SINT's high levels of dilution and capital raising concerns are causing investors to lose confidence in the stock.

Generated by AI

Topics

Of the messages about SINT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	89.87%
Analysts	—	—	—	4.43%
Controversies	—	—	—	2.53%
Earnings	—	—	—	1.27%
Macro	—	—	—	0%
Technical Analysis	—	—	—	1.9%

Announcements· Sep 3

SINTX Technologies published a landmark study demonstrating that its silicon nitride material exhibits broad-spectrum antiviral activity, including a 99.97% reduction in SARS-CoV-2 within 10 minutes.
The study's findings support the use of silicon nitride as a next-generation infection-prevention additive, with potential applications in wound dressings, surgical sutures, masks, hospital bedding, and HEPA filters.
The company's silicon nitride material releases nitrogen-based species that damage viral RNA and proteins without harming surrounding tissue, offering safety advantages over copper, silver, or zinc.

Technical Analysis· Feb 19

The price of $SINT has shown a bullish reversal and is forming a tightening range, with a potential pivot over its local lower high for confirmation.
The stock is testing key levels, including a support level at $4.80 and a resistance level at $5.30, with volume still flowing and large scalps happening.
The 200-day SMA on the daily chart is at $4.87, with some room for daily movement to the left, and the stock is also showing signs of being overbought on the stochastic oscillator.

Generated by AI

Community

Of the messages about SINT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	42.49%
Newcomers	—	—	0%	57.51%

Regulars· Aug 12

Sintx Technologies has been directly selling shares into the market to strengthen liquidity, and has approximately $3.6 million in cash and $5.1 million in ATM capacity.
A deal between Sintx and Varian Medical, which invested in Sintx's partner Ned Medical, has been validated and is on record, despite not being disclosed by Sintx management.
Sintx's technology is considered valuable, with Varian investing in it and Sintx's material being essential for Ned's Combisphere product, and Sintx's patent could have led to FDA clearance with Zimmer in 30 days.

Newcomers· Sep 3

Newcomers are focused on the low float of $SINT, which could lead to significant price movements.
Some newcomers are watching $SINT closely due to its recent price spikes and a machine learning sell prediction.
Others are taking a cautious approach, wondering if the recent sell alert is a smart exit or too early to bail.

Generated by AI

SINTX Technologies

Social

Aug 13

Bullish· Oct 21

Bearish· Oct 20

Announcements· Sep 3

Technical Analysis· Feb 19

Regulars· Aug 12

Newcomers· Sep 3

SINTX sponsors educational program on silicon nitride implants

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

SINTX regains Nasdaq compliance with stockholders’ equity

SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement

H.C. Wainwright reiterates Buy on SINTX Tech stock, $10 target

Also Discussed

SINTX Technologies, Inc. Common Stock

Company Information

Location

SINTX sponsors educational program on silicon nitride implants

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

SINTX regains Nasdaq compliance with stockholders’ equity

SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement

H.C. Wainwright reiterates Buy on SINTX Tech stock, $10 target

Also Discussed

Social

Aug 13

Bullish· Oct 21

Bearish· Oct 20

Announcements· Sep 3

Technical Analysis· Feb 19

Regulars· Aug 12

Newcomers· Sep 3